Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P11413: Variant p.Arg387Cys

Glucose-6-phosphate 1-dehydrogenase
Gene: G6PD
Feedback?
Variant information Variant position: help 387 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Cysteine (C) at position 387 (R387C, p.Arg387Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In NSHA; Guadajalara and Mount Sinai; class I. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 387 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 515 The length of the canonical sequence.
Location on the sequence: help AEVRLQFHDVAGDIFHQQCK R NELVIRVQPNEAVYTKMMTK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 515 Glucose-6-phosphate 1-dehydrogenase
Binding site 370 – 370
Binding site 393 – 393
Binding site 395 – 395
Modified residue 403 – 403 N6-acetyllysine
Mutagenesis 386 – 386 K -> Q. Impairs dimerization and reduces catalytic activity.
Mutagenesis 386 – 386 K -> R. Does not impair dimerization and catalytic activity.
Mutagenesis 403 – 403 K -> Q. Impairs dimerization and reduces catalytic activity in cells under oxidative stress.
Mutagenesis 403 – 403 K -> R. Does not impair dimerization and catalytic activity.



Literature citations
New glucose-6-phosphate dehydrogenase mutations from various ethnic groups.
Beutler E.; Westwood B.; Prchal J.T.; Vaca C.S.; Bartsocas C.S.; Baronciani L.;
Blood 80:255-256(1992)
Cited for: VARIANTS NSHA PRO-198; CYS-387; LEU-394; ASP-410 AND PRO-439; VARIANT MEXICO CITY GLN-227; VARIANT IERAPETRA SER-353; G6PD Mount Sinai: a new severe hemolytic variant characterized by dual mutations at nucleotides 376G and 1159T (N126D).
Vlachos A.; Westwood B.; Lipton J.M.; Beutler E.;
Hum. Mutat. Suppl. 1:S154-S155(1998)
Cited for: VARIANT NSHA CYS-387; VARIANT ASP-126;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.